Health Care • Biotechnology: Commercial Physical & Biological Resarch
$359.41 ▼ -16.69
(-4.44%)
MKT CAP: $17.16B • VOL: 1.50M
52W L $146 52W H $380
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$302
MEDIAN
$403
MEAN
$410
HIGH
$489
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CRL TAPE
CRL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $434.89 | $413.32 | 2025-02-14 | $327.06 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $452.86 | $424.10 | 2025-02-06 | $337.85 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $409.73 | $395.35 | 2025-01-29 | $345.03 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $366.60 | — | 2025-01-17 | $352.22 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $316.28 | $341.44 | 2025-01-09 | $319.87 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $427.70 | $373.79 | 2024-12-18 | $312.69 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $348.63 | $363.00 | 2024-12-04 | $334.25 | -4.3% | 48% | C |